Sofosbuvir/Velpatasvir for Patients with Chronic Genotype 3 HCV Infection with Compensated Cirrhosis: Response to EASL Recommendations on Treatment of Hepatitis C 2018

The recently published “EASL Recommendations on Treatment of Hepatitis C 2018” are described as “primarily based on evidence from existing publications and presentations at international meetings.” We agree with this approach that prioritizes publically available clinical data from randomized clinical trials over personal experience or preclinical information; however, the current guidelines have overlooked relevant Phase 3 results that have been published in peer-reviewed journals and/or presented at internationally recognized meetings regarding the use of sofosbuvir/velpatasvir for patients with chronic ge notype 3 HCV infection with compensated cirrhosis.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Source Type: research